Search company, investor...

Glycotope

glycotope.com

Founded Year

2001

Stage

Other Investors | Alive

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+60 points in the past 30 days

About Glycotope

Glycotope is a biopharmaceutical company in glycomics and its application for development of biopharmaceuticals.

Headquarters Location

Robert-Rossle-Str. 10

Berlin, 13125,

Germany

+49 (0) 30 9489 2600

Missing: Glycotope's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Glycotope's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Glycotope Patents

Glycotope has filed 1 patent.

The 3 most popular patent topics include:

  • Immune system
  • Clusters of differentiation
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/4/2018

8/25/2020

Clusters of differentiation, Immune system, Respiratory therapy, Immunology, Intensive care medicine

Grant

Application Date

9/4/2018

Grant Date

8/25/2020

Title

Related Topics

Clusters of differentiation, Immune system, Respiratory therapy, Immunology, Intensive care medicine

Status

Grant

Latest Glycotope News

Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting

Nov 8, 2022

Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting Berlin, Germany, 08 November, 2022 – Glycotope GmbH, a biotechnology company with a proprietary platform technology for developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces that it will present new data at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held in Boston, United States, between 8-12 November 2022. Patrik Kehler, Chief Scientific Officer of Glycotope GmbH commented: “We are looking forward to providing an update on the progress of our lead antibody program, GT-002, at SITC. The glycosylation-dependent binding of LYPD3 by GT-002 leads to markedly improved tumor-selectivity compared to protein binding antibodies resulting in reduced binding to healthy tissues. In addition, we will deliver a presentation on our GlycoTarget platform, showcasing how, by utilizing the same principle, our technology can be applied to significantly improve selectivity across other targets beside LYPD3.” Poster details are as follows: Abstract Number: 1347 Download here  from Thursday, 10 November 8am EST Title: Targeting of a cancer-associated LYPD3 glycoform for tumor therapy                                Poster hall: 10 November 2022, 9:00am - 9:00pm EST Abstract Number: 1346 Download here  from Friday, 11 November 8am EST Title: Antibodies against GlycoTargets as novel platform approach to address unmet needs in cancer therapy                                         Poster hall: 11 November 2022, 9:00am - 9:00pm EST Abstracts will be available on SITC’s website located at www.sitcancer.org at 8am EST on Nov. 7, 2022 Contact Information:

Nov 8, 2022
Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting Glycotope GmbH announces that it will present new data at the 2022 Society for Immunotherapy of Cancer Annual Meeting, being held in Boston, United States, between 8-12 November 2022. SciBase announces collaboration to detect skin barrier dysfunction in infants SciBase Holding AB announced that it has signed an agreement with Johnson & Johnson Consumer Inc. to collaborate on the development of a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants. Sequana Medical to present at Jefferies 2022 London Healthcare Conference Sequana Medical NV announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, taking place from 15 to 17 November 2022. Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering Marinus Pharmaceuticals, Inc.
Nov 8, 2022
Asensus Surgical Announces Ludwig Maximilians University in Germany to Initiate Senhance Pediatric Surgery Program Asensus Surgical, Inc. today announced that the Dr. von Hauner Children’s Hospital at the Ludwig Maximilians University Munich (“LMU”), has entered into an agreement to lease and utilize a Senhance® Surgical System. Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its primary vaccination Phase II study in the Philippines and heterologous booster vaccination Phase II study in United Arab Emirates in respect of its recombinant COVID-19 vaccine ReCOV. Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting Glycotope GmbH announces that it will present new data at the 2022 Society for Immunotherapy of Cancer Annual Meeting, being held in Boston, United States, between 8-12

Glycotope Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Glycotope Rank

Glycotope Frequently Asked Questions (FAQ)

  • When was Glycotope founded?

    Glycotope was founded in 2001.

  • Where is Glycotope's headquarters?

    Glycotope's headquarters is located at Robert-Rossle-Str. 10, Berlin.

  • What is Glycotope's latest funding round?

    Glycotope's latest funding round is Other Investors.

  • Who are the investors of Glycotope?

    Investors of Glycotope include Jossa Arznei.

  • Who are Glycotope's competitors?

    Competitors of Glycotope include PhaseBio Pharmaceuticals, CMC Biologics, Kythera Biopharmaceuticals, ActoGeniX, Cubist Pharmaceuticals and 12 more.

Compare Glycotope to Competitors

C
Celgen Biopharmaceuticals

Shanghai Celgen Biopharmaceutical is a bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgen's main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgen's Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.

S
Sarossa Capital

Sarossa, formerly Antisoma, is an investment holding and management company whose principal activity is investment in and growth and development of businesses which present opportunities for value creation.

Bird Rock Bio Logo
Bird Rock Bio

Bird Rock Bio, formerly RuiYi, is a clinical stage biopharmaceutical company focused on developing immuno-inflammatory regulators. The company's strategy leverages biologic targets with substantial human proof of mechanism for the development of novel, best in class therapeutic antibodies with significant clinical and commercial differentiation.

Aphios Logo
Aphios

Biopharmaceutical company developing enabling technology platforms and enhanced natural therapeutics for certain infectious diseases, cancers and CNS disorders. Ehanced therapeutics include small molecules from medicinal plants and marine organisms, and improved drug delivery formulations of protein macromolecules and hydrophobic anticancer drugs.

I
Intas Biopharmaceuticals

Intas Biopharmaceuticals Limited is a biopharmaceutical company based out of Ahmedabad, Gujarat, India. Since launch of biotechnology operations in May 2000, Research & Development (R&D) and Manufacturing of Biopharmaceutical products with a special focus on Oncology (Cancer) are the major thrust areas for the company.nIntas Biopharmaceuticals is India's first and only biopharmaceuticals company to receive European Union -Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility.

Protemix Logo
Protemix

Protemix is a biopharmaceutical company that discovers, develops and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and complications.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.